Petros Retained Earnings from 2010 to 2024

PTPI Stock  USD 0.26  0.01  4.00%   
Petros Pharmaceuticals' Retained Earnings are decreasing with slightly volatile movements from year to year. Retained Earnings are estimated to finish at about -93.9 M this year. Retained Earnings is the cumulative amount of net income that Petros Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-98.9 M
Current Value
-93.9 M
Quarterly Volatility
40.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Petros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Petros Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 509.3 K, Income Tax Expense of 5.9 B or Tax Provision of 0.0, as well as many indicators such as Price To Sales Ratio of 0.5, Dividend Yield of 145 or PTB Ratio of 0.33. Petros financial statements analysis is a perfect complement when working with Petros Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Petros Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.

Latest Petros Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Petros Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Petros Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Petros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (98.89 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Petros Retained Earnings Regression Statistics

Arithmetic Mean(31,479,979)
Coefficient Of Variation(127.32)
Mean Deviation35,758,452
Median(1,681,269)
Standard Deviation40,081,454
Sample Variance1606.5T
Range97.2M
R-Value(0.88)
Mean Square Error389.2T
R-Squared0.78
Significance0.000015
Slope(7,890,304)
Total Sum of Squares22491.3T

Petros Retained Earnings History

2024-93.9 M
2023-98.9 M
2022-90.7 M
2021-70.7 M
2020-61.7 M
2019-41.1 M

About Petros Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Petros Pharmaceuticals' Retained Earnings, to determine how well the company is positioned to perform in the future. Although Petros Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Retained Earnings-98.9 M-93.9 M

Currently Active Assets on Macroaxis

When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:
Check out the analysis of Petros Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.80)
Revenue Per Share
0.99
Quarterly Revenue Growth
(0.29)
Return On Assets
(0.31)
Return On Equity
(0.64)
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.